Research

We are a multidisciplinary research lab that applies engineering techniques and stem cell technologies to create in vitro biomimetic models for human heart disease. We use human induced pluripotent stem cells (iPSCs) from patients to generate cardiomyocytes (iPSC-CMs). This methodology allows us to understand how patient genetics drive cardiac disorders in a dish. Moreover, iPSC-CMs can be utilized to create 3D engineered heart tissues (EHTs), which more closely mimic the environment of the human heart. In addition, biophysical and biochemical stimulations can be applied further to simulate the complex pathophysiological niche of a diseased heart. This patient-specific preclinical model enables us to elucidate the pathogenesis of both acquired and genetic cardiomyopathies and test for candidate therapeutics. 

Colorful stained cells as seen under a microscope.

Investigating genetic mitochondrial cardiomyopathies using the iPSC model

Mitochondrial cardiomyopathies represent an important class of inherited heart failure, yet have been challenging to study due to a lack of proper model systems. We have developed a technology that allows us to generate metabolically mature iPSC-CMs that closely resemble the metabolism and mitochondrial function of adult heart cells. This opens up new avenues to unravel the mechanism of mitochondrial cardiomyopathies.

Modeling physiological and pathological hypertrophy in EHTs

In adaptation to increased mechanical loading, the human heart undergoes physiological or pathological hypertrophy. Physiological hypertrophy is associated with increased or preserved cardiac function, whereas pathological hypertrophy is associated with decreased cardiac function. How different patterns of biomechanical stimulations result in the divergent outcomes is unclear. This project will utilize engineered heart tissue to model physiological and pathological hypertrophy, and identify new targets for combating pathological hypertrophy.